Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system.
Saved in:
| Title: | Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system. |
|---|---|
| Authors: | Gochi AM; Department of Surgery, UCSF East Bay, Oakland, Calif., Jeffs S; Duke University School of Medicine, Duke University, Durham, NC., Hung YY; Division of Research, Kaiser Permanente Northern California, Pleasanton, Calif., Yang J; Division of Research, Kaiser Permanente Northern California, Pleasanton, Calif., Wang T; Bristol Myers Squibb Company, New York, NY., Okano G; Bristol Myers Squibb Company, New York, NY., Rosenblatt L; Bristol Myers Squibb Company, New York, NY., Villacorta R; Bristol Myers Squibb Company, New York, NY., Velotta JB; Division of Thoracic Surgery, The Permanente Medical Group, Inc, Oakland, Calif.; Department of Surgery, UCSF, San Francisco, Calif.; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, Calif. |
| Source: | JTCVS open [JTCVS Open] 2025 Oct 15; Vol. 28, pp. 632-653. Date of Electronic Publication: 2025 Oct 15 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: Netherlands NLM ID: 101768541 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-2736 (Electronic) Linking ISSN: 26662736 NLM ISO Abbreviation: JTCVS Open Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
